OTCMKTS:DTCFF Defence Therapeutics (DTCFF) Stock Price, News & Analysis $0.76 0.00 (0.00%) As of 05/12/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About Defence Therapeutics Stock (OTCMKTS:DTCFF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Defence Therapeutics alerts:Sign Up Key Stats Today's Range$0.76▼$0.7650-Day Range$0.62▼$1.0052-Week Range$0.27▼$1.16VolumeN/AAverage Volume17,215 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewDefence Therapeutics Inc. engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.Read More… Receive DTCFF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Defence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DTCFF Stock News HeadlinesDefence Therapeutics Inc.April 30, 2025 | barrons.comDefence Therapeutics Inc (DTC.DU)February 9, 2025 | ca.finance.yahoo.comWarning: Massive IPO Predicted for May 14?The #1 venture capitalist in America predicts that the biggest IPO in history will take place on Wednesday, May 14. And as Fortune has written, this IPO is “larger than any IPO valuation in history”… May 14, 2025 | Paradigm Press (Ad)Defence Therapeutics Secures $3.9 Million to Boost Biotech InitiativesJanuary 31, 2025 | tipranks.comDefence Therapeutics Strengthens Patent Portfolio, Secures Market ExclusivityJanuary 7, 2025 | markets.businessinsider.comDefence Therapeutics Strengthens Leadership with Key AppointmentsDecember 20, 2024 | markets.businessinsider.comDefence Therapeutics to License Accum TechnologyNovember 29, 2024 | tipranks.comDefence Therapeutics Welcomes Radiopharmaceutical ExpertNovember 15, 2024 | markets.businessinsider.comSee More Headlines DTCFF Stock Analysis - Frequently Asked Questions How have DTCFF shares performed this year? Defence Therapeutics' stock was trading at $0.3901 at the beginning of 2025. Since then, DTCFF stock has increased by 94.2% and is now trading at $0.7578. View the best growth stocks for 2025 here. How do I buy shares of Defence Therapeutics? Shares of DTCFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:DTCFF CIKN/A Webdefencetherapeutics.com Phone514 947 2272FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (OTCMKTS:DTCFF) was last updated on 5/14/2025 by MarketBeat.com Staff From Our PartnersGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s third-term comments grabbed headlines, but the bigger story is what he’s planning next. A new report ...Porter & Company | SponsoredSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMAY 14: New IPO 350X Bigger Than Amazon IPO?The #1 venture capitalist in America predicts that the biggest IPO in history will take place on Wednesday, Ma...Paradigm Press | SponsoredA New Economic Shift – How You Can PrepareWhile everyone's focused on the Fed and interest rates... most investors are missing the real story. There'...InvestorPlace | SponsoredDrop these 5 stocks now!You think the volatility is over? Think again … Because it’s just getting started. In fact, according...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Defence Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Defence Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
